SAB Biotherapeutics, Inc. SABS
Set alert
3.35 USD +0.12 +3.72%
At close · Oct 30
3.35 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
3.11 Day range 3.37
2.44 52-week range 5.15
- YTD
- -10.43%
- 1 year
- +11.30%
- Open
- 3.20
- Prev close
- 3.23
- Mkt cap
- 304.80M
- Vol
- 741.05K
- Avg vol
- 542.09K
- EPS
- -1.29
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.11
- High
- 3.37
- Forward P/E
- -1.56
- Beta
- 0.64
- Short ratio
- 1.22
- Inst. own
- 34.25%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 3.29
- 200-d avg
- 3.35
- 1y target
- 12.40
News
3 days ago globenewswire.com
SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET
MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1…
-
2 weeks ago benzinga.com
FDA Provides Fast Track Designation SAB Biotherapeutics' SAB-142 To Treat Stage 3 Type 1 Diabetes
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune…